Evidence map›Paper›PMID 38961395›Full record

ArticleJournal of translational medicine2024

Accumulation of liposomes in metastatic tumor sites is not necessary for anti-cancer drug efficacy.

Jessica Kalra, Jennifer Baker, XuXin Sun, Alastair Kyle, Andrew Minchinton, Marcel B Bally

Abstract read
In one paragraph

Article in Journal of translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jessica KalraExperimental Therapeutics, BC Cancer Research Institute, Vancouver, BC, Canada. jessica.kalra@ubc.ca.ORCID 0009-0004-3383-6901
Jennifer BakerIntegrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.
XuXin SunExperimental Therapeutics, BC Cancer Research Institute, Vancouver, BC, Canada.
Alastair KyleIntegrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.
Andrew MinchintonIntegrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.
Marcel B BallyExperimental Therapeutics, BC Cancer Research Institute, Vancouver, BC, Canada.

Funding

Canadian Cancer Society 702491Canadian Cancer Society 705290CIHR MOP-102611
6 · The paper itself

Abstract

backgroundThe tumor microenvironment is profoundly heterogeneous particularly when comparing sites of metastases. Establishing the extent of this heterogeneity may provide guidance on how best to design lipid-based drug delivery systems to treat metastatic disease. Building on our previous research, the current study employs a murine model of metastatic cancer to explore the distribution of ~ 100 nm liposomes.

methodsFemale NCr nude mice were inoculated with a fluorescently labeled, Her2/neu-positive, trastuzumab-resistant breast cancer cell line, JIMT-1

resultsA significant amount of inter-vessel heterogeneity for DiR distribution was observed, with most tumor blood vessels showing little to no presence of the DiR-labelled liposomes. Further, there was limited extravascular distribution of DiR liposomes in the perivascular regions around DiR-positive vessels. While all OT tumors contained at least some DiR-positive vessels, many metastases had very little or none. Despite the apparent limited distribution of liposomes within metastases, two liposomal drug formulations, Irinophore C and Doxil, showed similar efficacy for both the OT and IC JIMT-1

conclusionThese findings suggest that liposomal formulations achieve therapeutic benefits through mechanisms that extend beyond the enhanced permeability and retention effect.

Indexed as

Antineoplastic AgentsLiposomesMice, NudeNeoplasm MetastasisAnimalsCell Line, TumorFemaleHumansMiceTreatment OutcomeAntineoplastic AgentsLiposomesEnhanced permeability and retention effectInter- and intra-tumor heterogeneityLiposomesMetastases/metastasisPre-clinical modelsTranslational researchTumor microenvironment

Identifiers

PMID38961395
PMCPMC11223361

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.